march cigarett volum shipment vs
nielsen w/e march
 eek end march us cigarett volum ere combin ith first tw month
volum run better accord nielsen us cigarett industri volum end
differ ith data expand last period sudden acceler volum larg
due pantri load easi comp declin e-cigarett sale yoy also help
bat e-cigarett sale ere mom yoy ere ith market share vs dec
closed-tank e-cigarett ere dow yoy grew mom might benefit closur vape shop think
bat us cig e-cig volum ill data today cig e-cig support thesi
zyn sale grow th strong sequenti sale grow th eek end feb impli
sw ill like sell-through can publish estim assum zyn
sell-through can
 think six key reason strong cigarett perform pantri load due clearli evid
tabl tobacco compani close tank e-cigarett dow yoy cannibalis cigarett reduc
 vape shop larg sell open-tank shut dow hile grocer sell cigarett remain open benefit oil
price declin hile neg impact higher unemploy yet come due extend unemploy benefit
easier comp shift travel retail sale local store
bat expect us industri cigarett volum grow th imb expect think altria
cigarett volum guidanc conserv comp go get easier next month notabl
cigarett volum grow th reach low eek end juli ever think industri ill
chang guidanc result due difficult-to-forecast recession-induc headw ind
 note manufactur increas price effect feb
close tank e-cigarett industri sale ere mom dow yoy
juul sale mom dow yoy juul privat entiti altria passiv invest stake
juul juul stop sell mint fda announc ban closed-tank e-cigarett flavor exclud tobacco
menthol jan effect feb
march fda ask feder judg grant extens submit pmta applic cite except
circumst present global coronaviru outbreak agenc propos move deadlin septemb
may think like grant anti-tobacco lobbi signal ouldnt oppos fda request
cigarett volum data better nielsen
pantri load due evid tobacco compani
bloomberg data close march
bloomberg data close march
bloomberg data close march
fda compani reports/websit nielsen barclay research march fda ask judg delay e-cigarett pmta deadlin day sep
tobacco-rel item hhs/fda fall agenda
offic inform regulatori affair
vote begun extel survey extrem import us key metric judg
appreci research pleas vote ith link take minut time make huge differ
us ould grate support follow ing
tobacco gaurav jain mandeep sangha
beverag laurenc hyatt ew mitchel
link previou research
sw edish match play next decad
inc iqo price discount vs lboro iden
bat/pmi materi impact yet tobacco
european consum stapl tobacco esg sustain strategi
sw edish match cigar manufactur dominican republ suspend tw eek
altria/bat oper resili focu post altria impact
pmi detail fx sensit
us tobacco ill opec benefit repeat
altria/bat bloomberg exit take polit tail risk tabl
altria/bat feb cig volum shipment vs nielsen
inc pmi grow ep post feb
imperi brand plc orsen ngp loss lead groundhog day feb
altria/bat jan cig volum shipment vs nielsen feb
inc last ep cut juul ritedow feb
british american tobacco plc rai us volum declin jan
altria/bat dec cig volum shipment vs nielsen jan
global consum stapl jan
global tobacco fda e-cig ban advantag bat juul flavor cigar ban jan
sw edish match address bearish pushback dec
japan tobacco japan close cigarillo tax gap dec
altria/bat report us cig volum bat e-cig begin grow rapidli dec
european consum stapl trump back aw ay ban e-cig flavor focu turn congress
altria/bat fda drop us cig nicotin reduct return menthol ban flavor cigar rulemak also get delay
altria/bat report us cig volum e-cig stall
imperi brand plc new chairperson dividend stabil still grow ing ep support stock
british american tobacco plc meet ith cfo
inc long journey rebuild trust
global tobacco juul uk europ financi oct
sw edish match zyn off-set flavor cigar oe pt sek oct
european consum stapl vape epidem fallaci e-cig flavour ban oct
european consum stapl pm-mo chang exchang ratio aug
inc iqo back track upgrad ow juli
european consum stapl smoke signal second deriv us volum turn posit atermelon blueberri
mentholet analys possibl implic menthol ban dec
smoke signal kick tyre ith juul sep
smoke signal juul disrupt come tobacco juli
imperi brand initi heat burn dow may
gaurav jain herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill directli
indirectli relat specif recommend view express research report
nielsen materi contain report repres nielsen estim repres fact nielsen neither review ed
approv report and/or statement made herein
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
research report prepar hole part equiti research analyst base outsid us ho
registered/qualifi research analyst ith finra
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
research analyst employ outsid us affili barclay capit inc registered/qualifi research analyst
 ith finra non-u research analyst may associ person barclay capit inc hich finra member
therefor may subject finra rule restrict commun ith subject compani public appear
trade secur held research analyst account
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target altria base price-to-earnings valuat last tw decad altria trade
averag fw multipl higher cigarett volum declin regulatori uncertainti manag attempt sell us
busi p/core tobacco ep pressur multipl near term valu altria price-to-earnings add addit
valu per share juul crono get price target usd
risk may imped achiev barclay research valuat price target fda regul drastic
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog consid british american tobacco valuat use p/e-bas approach deriv
target multipl ith refer bat tobacco peer group make adjust busi mix leverag grow th
prospect appli multipl ep result round price target
risk may imped achiev barclay research valuat price target regulatori agenda
fda ill domin headlin everi month like creat period heighten volatil altria aggress ith
iqo could lead signific up-front invest disrupt market share equilibrium damag market profit
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
